HAMPHARMA

HAMPHARMA has been active since 1982 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €30,800 and a net result of €143,531. Equity remains stable across the filed financial years (±0.4% per year). Its solvency ranks better than 14% of 12,411 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.8% (low).